Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Using a lamellar structure as a delivery system, the Sulidin® Nimesulide LPS gel provides enhanced percutaneous penetration of Nimesulide and reduced yellow staining on the skin. LPS Technology worldwide patents are pending. More
BIOIBERICA would extend the right to use its CTD dossier for registration of Cartisorb® (Glucosamine Sulfate sachets) as a branded generic drug (to be marketed under Cartisorb® brand name or other brand name) on a local level. More
Capsaicin, the active ingredient found in red-hot peppers, is used mainly for the relief of chronic pain of rheumatoid arthritis and osteoarthritis More
FMC Pharma is devoted to the treatment of osteoarthritis through the development of products, marketing methodologies and out-licensing opportunities. More
BIS010 is a semi-synthetic plant origin polysaccharide demonstrating a potential modifying effect of the biologic activity of the joints. More
Suite of proprietary collagen-binding peptides derived from bone sialoprotein (BSP) that are effective in promoting bone repair and regeneration. More
New local approach in Osteoarthritis: INTRA-ARTICULAR CLODRONATE More
TRx Pharma is currently looking for a partner in the US only to copromote RELAMINE More
A diagnostic and therapeutic secreted target protein that is upregulated in a subset of human patients with Osteoarthritis. It is a strong regulatory candidate for the transformation of maintenance chondrocytes into digestive aggravators of OA. More
Identification and use of RAR antagonists to induce bone and cartilage formation More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us